

**Faculty Disclosure Information**  
**31<sup>st</sup> Annual Multidisciplinary Symposium on Breast Disease**  
February 13-15, 2026

University of Florida College of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control a CME activity's content, including faculty, planners, reviewers, and/or others, must disclose all financial relationships with ineligible companies (commercial interests). Conflict of interest information for the CME Advisory Committee members can be found on the following website: <https://cme.ufl.edu/disclosure>. No one else in a position to control content has any financial relationships to disclose. All relevant financial relationships have been mitigated.

**The following speakers and planning committee members have an affiliation/financial interest in the following areas:**

Graham Colditz, MD	<b>Consulting Fee:</b> Lunit
Coy Heldermon, MD	<b>Consulting Fee:</b> Cardinal Health, Chiesi (Relationship has ended), Regenx bio (Relationship has ended), Mallinckrodt Pharmaceuticals (Relationship has ended), Curio Sciences (Relationship has ended), Targeted oncology (Relationship has ended), Intrinsic Specialty Solutions (Relationship has ended) <b>Grant or research support:</b> Sanofi S.A.
Kelly Hunt, MD	<b>Grant or research support:</b> Cairn Surgical, Lumicell, Eli Lilly & Co. (Relationship has ended) <b>Advisor:</b> ArmadaHealth (Relationship has ended) <b>Membership on Advisory Committees or Review Panels, Board Membership, etc.:</b> AstraZeneca, Daiichi Sankyo, Inc <b>Honoraria:</b> Merck (Relationship has ended)
Linda Moy, MD	<b>Membership on Advisory Committees or Review Panels, Board Membership, etc.:</b> Bracco Diagnostics, Inc., American College of Radiology, Society of Breast Imaging
Habib Rahbar, MD	<b>Grant or research support:</b> Guerbet, LLC
Pedram Razavi, MD, PhD	<b>Grant or research support:</b> Novartis Corporation Pharmaceuticals, AstraZeneca, Tempus, Guradant Health, SAGA, Myriad, Grail, Personalis, Biodesi, Foresight <b>Consulting Fee:</b> Novartis Corporation Pharmaceutical, AstraZeneca, Prelude Therapeutics (Relationship has ended), Regor Pharmaceuticals (Relationship has ended), Foresight. Biovica (Relationship has ended), SAGA (Relationship has ended), Neogenomics (Relationship has ended) <b>Advisor:</b> Lilly, Tempus, Pathos AI, Myriad (Relationship has ended) <b>Grant or research support:</b> Sophia Genetics
Mark Robson, MD	<b>Grant or research support:</b> AstraZeneca, Merck, Artios Pharma
Andrew Seidman, MD	<b>Honoraria:</b> AstraZeneca, Gilead Sciences, Inc., Lilly, Merck, Novartis Corporation Pharmaceuticals, Genentech

**The following speakers and planning committee members have no actual or potential conflict of interest in relation to this activity:**

Carmen Bergom, MD, PhD, Ben Calhoun, MD, PhD, Stephanie Crawford, Armando Giuliano, MD, Rebel Jones, Joshua Levine, MD, Shahla Masood, MD, Olufunmilayo Olopade, MBBS, Gwendolyn Quinn, PhD, Alice Rhoton-Vlasak, MD, Melvin Silverstein, MD, Carmen Smotherman, Alastair Thompson, MD, Susan Weinstein, MD

No one else in a position to control content, including other speakers, Planning Committee members or administrative staff, has any financial relationships to disclose.